Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
P/E(ttm) 18.91
PID's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 18.91 )
Ranked among companies with meaningful P/E(ttm) only.
PID' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 19.02
Current: 18.91
0
19.02
PE(NRI) 18.91
PID's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 18.91 )
Ranked among companies with meaningful PE(NRI) only.
PID' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 19.02
Current: 18.91
0
19.02
P/B 1.59
PID's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 1.59 )
Ranked among companies with meaningful P/B only.
PID' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.62
Current: 1.59
0
1.62

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.77
PID's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 3.77 )
Ranked among companies with meaningful Dividend Yield only.
PID' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.19
Current: 3.77
0
4.19
Yield on cost (5-Year) 3.77
PID's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 3.77 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PID' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.19
Current: 3.77
0
4.19

More Statistics

Short Percentage of Float0.00%
52-Week Range $12.33 - 15.02
Shares Outstanding (Mil)51,600,000.00
» More Articles for PID

Headlines

Articles On GuruFocus.com
How Fast Can a Big Bank Grow Its Deposits? Feb 18 2017 
Stocks That Are Reaching Their 3-Year Lows Feb 18 2017 
3M Company Hikes Dividend by 6% but Trades at an Elevated Valuation Feb 18 2017 
Weekly Top Insider Buys Highlight for the Week of Feb. 17 Feb 18 2017 
Will Mid-Sized Cities Rally the US Housing Market in 2017? Feb 18 2017 
Dow Jones and Nasdaq Reach New Highs on Friday Feb 17 2017 
Prem Watsa Ends Period of Shorting Market With $1.2 Billion Loss Feb 17 2017 
How Much Will Genesis Energy Raise Distributions in 2017? Feb 17 2017 
Which Dividend Achiever Utility Is Better – Dominion or PPL? Feb 17 2017 
Reasons to Own This MLP for the Long Term Feb 17 2017 

More From Other Websites
GlaxoSmithKline’s Consumer Healthcare Reports Growth in 4Q16 Feb 16 2017
GlaxoSmithKline’s Vaccines Business Reported Growth in 4Q16 Feb 15 2017
4Q16 Performance of GlaxoSmithKline’s Business Segments Feb 14 2017
Novartis’s Innovative Medicines Segment in 4Q16 Feb 01 2017
PotashCorp in 4Q16: Nitrogen Prices Added Salt to the Wound Jan 30 2017
Novartis’s 4Q16 Estimates: Innovative Medicines Segment Jan 23 2017
How Did Novartis’s Generics Business Perform in 3Q16? Jan 17 2017
How GlaxoSmithKline’s Pharmaceuticals Segment Has Performed Dec 30 2016
4 High Dividend ETFs Under $20 Dec 13 2016
PowerShares Announces Listing Transfer for 27 ETFs Nov 23 2016
How Sandoz Performed for Novartis in 3Q16 Nov 17 2016
How Tresiba Helps Novo Achieve Its Growth Targets Nov 03 2016
Victoza Dominates Global GLP-1 Class Nov 03 2016
Reading Novo’s Insulin Portfolio to Find Clues about Its Growth Nov 02 2016
US Still the Largest Market for Novo Nordisk Nov 01 2016
Why Did PotashCorp’s Nitrogen Prices Fall in 3Q16? Nov 01 2016
How Much Is the Return Opportunity for Novo Nordisk in 3Q16? Oct 25 2016
Novartis’s 3Q16 Estimates: Will Alcon Recover Its Growth? Oct 24 2016
Novartis’s 3Q16 Estimates: Innovative Medicines Segment Oct 24 2016
5 Best Smart Beta ETFs That Pay Dividends (PID, ICF) Oct 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK